Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AndroMETa-CRC-533: Telisotuzumab adizutecan combinations in metastatic colorectal cancer
2024-512981-33-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, open-label trial of telisotuzumab adizutecan in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Objective response rate (ORR) by investigator (Substudy 1 and 2). Planned start Jul 2025; status: authorised.
02
Drugs
telisotuzumab adizutecan
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2024-512981-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512981-33-00.